TY - JOUR
T1 - Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme
T2 - A Systematic Review and Meta-Analyses
AU - Anton, Jellyca
AU - Sudibio, Sudibio
AU - Handoko, Handoko
AU - Permata, Tiara Bunga Mayang
AU - Kodrat, Henry
AU - Nuryadi, Endang
AU - Sofyan, Henry
AU - Susanto, Eka
AU - Mulyadi, Rahmad
AU - Aman, Renindra Ananda
AU - Gondhowiardjo, Soehartati
N1 - Funding Information:
The authors would like to thank Universitas Indonesia for funding this research through PUTI Grant with contract number ND-1575/UN2.F1.D1.4/PPM.00.00/2021. This study is a part of thesis in the fulfillment of the requirements for the degree of Radiation Oncology Specialist (Department of Radiation Oncology, dr. Cipto Mangunkusumo Hospital, University of Indonesia, Indonesia). Ethical approval was not required because this systematic review with meta-analysis used secondary data from the already published studies.
Publisher Copyright:
© 2021. All Rights Reserved.
PY - 2021
Y1 - 2021
N2 - Objective: The aim of this study is to evaluate the association of c-Met overexpression with survival of glioblastoma multiforme (GBM) patients. Methods: A systematic review with meta-analyses was conducted on related articles from PubMed, EBSCOhost, Scopus, and Cochrane databases with last updated search on October 31, 2020. A total of 7 studies regarding c-Met overexpression and overall survival (OS) and/or progression free survival (PFS) are included in this study. Results: All studies used immunohistochemistry to examine the expression of c-Met protein. The results showed that the positive rate of c-Met overexpression was detected in approximately 33,9% - 60,5% of GBM patients. c-Met overexpression was related to worse OS (HR: 1,74; 95% CI: 1,482-2,043; Z=6,756; p<0,001) and PFS (HR: 1,66; 95% CI: 1,327-2,066; Z=4,464; p<0,001) in GBM patients. Low heterogeneity of subjects was found in both OS and PFS analyses, I2 values were 7,8% and 0,0%, respectively. Conclusion: In conclusion, c-Met overexpression is significantly related to shorter OS and PFS in GBM patients, so c-Met can be considered as a potential prognostic indicator in GBM.
AB - Objective: The aim of this study is to evaluate the association of c-Met overexpression with survival of glioblastoma multiforme (GBM) patients. Methods: A systematic review with meta-analyses was conducted on related articles from PubMed, EBSCOhost, Scopus, and Cochrane databases with last updated search on October 31, 2020. A total of 7 studies regarding c-Met overexpression and overall survival (OS) and/or progression free survival (PFS) are included in this study. Results: All studies used immunohistochemistry to examine the expression of c-Met protein. The results showed that the positive rate of c-Met overexpression was detected in approximately 33,9% - 60,5% of GBM patients. c-Met overexpression was related to worse OS (HR: 1,74; 95% CI: 1,482-2,043; Z=6,756; p<0,001) and PFS (HR: 1,66; 95% CI: 1,327-2,066; Z=4,464; p<0,001) in GBM patients. Low heterogeneity of subjects was found in both OS and PFS analyses, I2 values were 7,8% and 0,0%, respectively. Conclusion: In conclusion, c-Met overexpression is significantly related to shorter OS and PFS in GBM patients, so c-Met can be considered as a potential prognostic indicator in GBM.
KW - c-Met
KW - glioblastoma multiforme
KW - prognosis
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85118768203&partnerID=8YFLogxK
U2 - 10.31557/APJCP.2021.22.10.3075
DO - 10.31557/APJCP.2021.22.10.3075
M3 - Article
AN - SCOPUS:85118768203
SN - 1513-7368
VL - 22
SP - 3075
EP - 3080
JO - Asian Pacific Journal of Cancer Prevention
JF - Asian Pacific Journal of Cancer Prevention
IS - 10
ER -
